Literature DB >> 24375079

Scaffold mining of kinase hinge binders in crystal structure database.

Li Xing1, Brajesh Rai, Elizabeth A Lunney.   

Abstract

Protein kinases are the second most prominent group of drug targets, after G-protein-coupled receptors. Despite their distinct inhibition mechanisms, the majority of kinase inhibitors engage the conserved hydrogen bond interactions with the backbone of hinge residues. We mined Pfizer internal crystal structure database (CSDb) comprising of several thousand of public as well as internal X-ray binary complexes to compile an inclusive list of hinge binding scaffolds. The minimum ring scaffolds with directly attached hetero-atoms and functional groups were extracted from the full compounds by applying a rule-based filtering procedure employing a comprehensive annotation of ATP-binding site of the human kinase complements. The results indicated large number of kinase inhibitors of diverse chemical structures are derived from a relatively small number of common scaffolds, which serve as the critical recognition elements for protein kinase interaction. Out of the nearly 4,000 kinase-inhibitor complexes in the CSDb we identified approximately 600 unique scaffolds. Hinge scaffolds are overwhelmingly flat with very little sp3 characteristics, and are less lipophilic than their corresponding parent compounds. Examples of the most common as well as the uncommon hinge scaffolds are presented. Although the most common scaffolds are found in complex with multiple kinase targets, a large number of them are uniquely bound to a specific kinase, suggesting certain scaffolds could be more promiscuous than the others. The compiled collection of hinge scaffolds along with their three-dimensional binding coordinates could serve as basis set for hinge hopping, a practice frequently employed to generate novel invention as well as to optimize existing leads in medicinal chemistry.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24375079     DOI: 10.1007/s10822-013-9700-4

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  33 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

Review 2.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

Review 3.  Protein kinases--the major drug targets of the twenty-first century?

Authors:  Philip Cohen
Journal:  Nat Rev Drug Discov       Date:  2002-04       Impact factor: 84.694

4.  Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism.

Authors:  Hidehisa Iwata; Shinichi Imamura; Akira Hori; Mark S Hixon; Hiroyuki Kimura; Hiroshi Miki
Journal:  Biochemistry       Date:  2011-01-10       Impact factor: 3.162

5.  Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.

Authors:  Jeffrey R Simard; Matthäus Getlik; Christian Grütter; Vijaykumar Pawar; Sabine Wulfert; Matthias Rabiller; Daniel Rauh
Journal:  J Am Chem Soc       Date:  2009-09-23       Impact factor: 15.419

Review 6.  Active and inactive protein kinases: structural basis for regulation.

Authors:  L N Johnson; M E Noble; D J Owen
Journal:  Cell       Date:  1996-04-19       Impact factor: 41.582

7.  Escape from flatland: increasing saturation as an approach to improving clinical success.

Authors:  Frank Lovering; Jack Bikker; Christine Humblet
Journal:  J Med Chem       Date:  2009-11-12       Impact factor: 7.446

8.  p38alpha MAP kinase C-terminal domain binding pocket characterized by crystallographic and computational analyses.

Authors:  J Jefferson P Perry; Rodney M Harris; Davide Moiani; Arthur J Olson; John A Tainer
Journal:  J Mol Biol       Date:  2009-06-06       Impact factor: 5.469

9.  Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.

Authors:  Haridasan V Namboodiri; Marina Bukhtiyarova; Joseph Ramcharan; Michael Karpusas; Younghee Lee; Eric B Springman
Journal:  Biochemistry       Date:  2010-05-04       Impact factor: 3.162

10.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.

Authors:  Christopher Pargellis; Liang Tong; Laurie Churchill; Pier F Cirillo; Thomas Gilmore; Anne G Graham; Peter M Grob; Eugene R Hickey; Neil Moss; Susan Pav; John Regan
Journal:  Nat Struct Biol       Date:  2002-04
View more
  7 in total

1.  Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells.

Authors:  Liv Johannessen; Thomas B Sundberg; Daniel J O'Connell; Raivo Kolde; James Berstler; Katelyn J Billings; Bernard Khor; Brinton Seashore-Ludlow; Anne Fassl; Caitlin N Russell; Isabel J Latorre; Baishan Jiang; Daniel B Graham; Jose R Perez; Piotr Sicinski; Andrew J Phillips; Stuart L Schreiber; Nathanael S Gray; Alykhan F Shamji; Ramnik J Xavier
Journal:  Nat Chem Biol       Date:  2017-08-14       Impact factor: 15.040

2.  Structure-Based Target-Specific Screening Leads to Small-Molecule CaMKII Inhibitors.

Authors:  David Xu; Liwei Li; Donghui Zhou; Degang Liu; Andy Hudmon; Samy O Meroueh
Journal:  ChemMedChem       Date:  2017-04-18       Impact factor: 3.466

3.  A Chemical Probe for Dark Kinase STK17B Derives Its Potency and High Selectivity through a Unique P-Loop Conformation.

Authors:  Alfredo Picado; Apirat Chaikuad; Carrow I Wells; Safal Shrestha; William J Zuercher; Julie E Pickett; Frank E Kwarcinski; Parvathi Sinha; Chandi S de Silva; Reena Zutshi; Shubin Liu; Natarajan Kannan; Stefan Knapp; David H Drewry; Timothy M Willson
Journal:  J Med Chem       Date:  2020-11-20       Impact factor: 7.446

4.  Redefining the Protein Kinase Conformational Space with Machine Learning.

Authors:  Peter Man-Un Ung; Rayees Rahman; Avner Schlessinger
Journal:  Cell Chem Biol       Date:  2018-05-31       Impact factor: 8.116

5.  Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR.

Authors:  Dilip Narayanan; Osman A B S M Gani; Franz X E Gruber; Richard A Engh
Journal:  J Cheminform       Date:  2017-07-04       Impact factor: 5.514

6.  IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models.

Authors:  Anjelika Gasilina; Gurdat Premnauth; Purujit Gurjar; Jacek Biesiada; Shailaja Hegde; David Milewski; Gang Ma; Tanya V Kalin; Edward Merino; Jarek Meller; William Seibel; José A Cancelas; Lisa Privette Vinnedge; Nicolas N Nassar
Journal:  PLoS One       Date:  2020-03-12       Impact factor: 3.240

Review 7.  Plasmodium Kinases as Potential Drug Targets for Malaria: Challenges and Opportunities.

Authors:  Lauren B Arendse; Susan Wyllie; Kelly Chibale; Ian H Gilbert
Journal:  ACS Infect Dis       Date:  2021-02-16       Impact factor: 5.084

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.